WO1994027610A1 - Mittel, enthaltend eine verbindung mit antiandrogener sowie eine verbindung mit kompetitiver, progesteronantagonistischer wirkung - Google Patents
Mittel, enthaltend eine verbindung mit antiandrogener sowie eine verbindung mit kompetitiver, progesteronantagonistischer wirkung Download PDFInfo
- Publication number
- WO1994027610A1 WO1994027610A1 PCT/EP1994/001756 EP9401756W WO9427610A1 WO 1994027610 A1 WO1994027610 A1 WO 1994027610A1 EP 9401756 W EP9401756 W EP 9401756W WO 9427610 A1 WO9427610 A1 WO 9427610A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- hydroxy
- methyl
- prophylaxis
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
Definitions
- the present invention relates to agents containing at least one compound with anti-androgenic (AA) and at least one compound with competitive, progesterone-gonistic (PA) activity. It relates in particular to agents of the specified type for the prophylaxis and treatment of prostate cancer and benign prostatic hyperplasia (BPH).
- AA anti-androgenic
- PA progesterone-gonistic
- Prostatic hyperplasia is a benign enlargement of the prostate that begins with the so-called “inner” prostate.
- the complaints are mainly due to the occurring obstructions of the urethra.
- the emptying of the bladder is difficult and residual ham retardations occur. Without surgery, urea poisoning can occur.
- the interstitium (stroma) and epithelium are involved to varying degrees in the enlargement of the prostate.
- a shift in the estrogen / androgen ratio in favor of the estrogens can be regarded as the cause.
- Various studies have shown that serum testosterone concentrations drop in older men; at the same time, the proportion of SHBG (sex hormone binding globuline, specific transport protein for steroids) increases, so that the bioavailability of androgens decreases even further.
- Combinations of various anti-hormones or hormone synthesis inhibitors also belong to the prior art for the treatment of prostate hyperplasia, for example combination of an aromatase inhibitor with an anti-androgen (DE-A-31 21 152), an anti-estrogen with an anti-androgenic substance (DE-A- 28 17 157) or an aromatase inhibitor with a 5 ⁇ -reductase inhibitor (WO87 / 05216; WO91 / 00731; WO92 / 18132).
- the object of the present invention is to provide medicaments which enable effective therapy of prostate carcinomas and, in general, also those which have become androgen-independent. At the same time, it would be desirable if such an agent were also suitable for the prophylaxis and therapy of benign prostatic hyperplasia.
- Such drugs are provided by the present invention.
- the agent according to the invention therefore has a synergistic effect for the indicated indications.
- a (pharmaceutically active) combination containing AA and PA was not previously known.
- the present invention also relates to the use of at least one compound with antiandrogenic (AA) and at least one compound with competitive, progesterone-antagonistic (PA) activity for the production of medicaments.
- AA antiandrogenic
- PA progesterone-antagonistic
- the invention relates to the use of the abovementioned compounds for the production of medicaments for the prophylaxis and for the treatment of prostate carcinoma and for the prophylaxis and for the therapy of benign prostatic hyperplasia (BPH).
- BPH benign prostatic hyperplasia
- PA progesterone-antagonistic
- the present invention therefore also relates to the use of at least one compound having a competitive, progesterone-antagonistic (PA) effect for the production of
- PA progesterone-antagonistic
- the weight ratio of the two components of the agent according to the invention can be varied within wide limits when used for the two indications described.
- AA and PA are used together, separately, simultaneously and / or chronologically, in a weight ratio of 1:40 to 25: 1, preferably 1: 1 to 5: 1, and in particular 1: 1 to 2: 1. Co-administration is preferred.
- Sequential treatment with the two components AA and PA of the combination according to the invention is also possible.
- the component given as the second component can be given at any time after the component applied first, as long as it becomes bioavailable in the patient to be treated at the same time as an effective amount of the component applied first.
- the antiandrogenic component can be given first and then the PA component.
- the treatment regimen for a patient suffering from prostate cancer or BPH can also be such that monotherapy with an antiandrogen is carried out as the first treatment measure, over a period of several weeks until no further growth inhibition of prostate cancer is achieved. This is followed by treatment with PA alone or AA and PA in combination, simultaneously or sequentially.
- AA and PA are administered in one dose unit or in separate dose units.
- All compounds which act as competitive antiandrogens i.e. those that mediate their AA effect through strong affinity for the androgen receptor.
- These AA-acting compounds can be of both steroidal origin and non-steroids.
- Suitable steroids are the compounds of the general formulas I and II:
- Rl and R ⁇ each like a hydrogen atom or both: »m another carbon-carbon bond or the methyl group ⁇ : - .
- R-3 is the acyl radical of an acid customary in steroid chemistry
- Y is an oxygen atom or the group H, OR4 with R ⁇ in the meaning of hydrogen, acyl or alkyl,
- Xl is a hydrogen or chlorine atom
- X2 is a hydrogen, fluorine or chlorine atom
- R * and R ⁇ each stand for hydrogen or both together the methylene group, X hydrogen, fluorine or chlorine and
- R 3 and R 4 represent the residue of an acid customary in steroid chemistry.
- acyl residue should be understood to mean the residues of the acids customary in steroid chemistry for the esterification of secondary and tertiary hydroxyl groups.
- Aliphatic carboxylic acids having 1 to 8 carbon atoms are preferred, such as, for example, acetic acid, propionic acid, butyric acid, valeric acid, isovaleric acid, caproic acid, oenanthic acid, etc.
- the esters of acetic acid are particularly preferred.
- Alkyl is to be understood as meaning lower alkyl groups with 1-5 carbon atoms, the methyl group being preferred.
- Typical compounds of general formula I are the 17-esters of, for example
- Typical compounds of the general formula II are, for example, 6-chloro-17ass-acetoxy-17a ⁇ -methyl-1,2, 2-methylene-D-homo-4,6-androstadiene-3J7-dione and 6-chloro-17 ⁇ -acetoxy-17ß -methyl-l, 2 ⁇ -methylene-D-homo-4,6-androstadiene-3J7a-dione.
- nonsteroidal antiandrogens are the compounds 2-methyl-N- [4-nitro-3- (trifluoromethyl) phenyl] propionamide (flutamide)
- 5 ⁇ -reductase inhibitors which prevent the conversion of testosterone into dihydrotestosterone are also suitable according to the invention as a compound with an AA effect.
- the compounds with antiandrogenic activity are administered in amounts of about 1 to 500 mg of cyproterone acetate, preferably 50 to 500 mg, per day or an equivalent amount of another antiandrogen.
- the dosage of the compounds with a competitive progesterone-antagonistic effect for the indications prostate cancer and benign prostatic hyperplasia is 20 - 200 mg onapristone per day or an equivalent amount of another compound with PA effect.
- the active ingredients can be processed with the additives, carrier substances and / or taste correctives customary in pharmaceutical pharmacy to methods customary in conventional methods.
- Tablets, coated tablets, capsules, pills, suspensions or solutions are particularly suitable for the preferred oral application.
- Oily solutions such as sesame oil or castor oil solutions are suitable for parenteral, in particular intramuscular, application.
- Solubilizers such as, for example, benzyl benzoate or benzyl alcohol, can be added to increase the solubility.
- the medicinal products formulated as above preferably contain 10 mg to 100 mg of onapristone and 50 mg to 100 mg of cyproterone acetate, or in each case the equivalent doses of another competitive progesterone antagonist and antiandrogen.
- composition of an AA tablet for oral administration Composition of an AA tablet for oral administration
- composition of a PA tablet for oral administration Composition of a PA tablet for oral administration
- composition of an AA / PA tablet for oral administration Composition of an AA / PA tablet for oral administration
- a tablet press is manufactured. If appropriate, the active compounds according to the invention, each with half of the additives indicated above, can also be pressed separately into a two-layer tablet.
- the tumor-inhibiting effect of the agent according to the invention is checked on the androgen-dependent R3327H prostate carcinoma of the rat:
- the R3327H prostate carcinoma was found as a spontaneous tumor in the dorsal prostate of a Copenhagen (Cop) rat and further transplanted.
- the tumor is androgen dependent, i.e. Castration of animals with established tumors almost completely inhibits tumor growth. After a few months, however, there is renewed growth (so-called "relapse").
- the R3327H tumor contains androgen and estrogen receptors as well as 5 ⁇ -reductase. It is very similar in its response to antiandrogens, estrogens or LHRH analogues and histologically to human prostate carcinoma and is therefore an almost ideal tumor model for the development of new prostate carcinoma therapeutics.
- test substances are dissolved in benzyl benzoate + castor oil (1 + 4) and the single dose in a volume of 0J ml / 100 body weight s.c. or p.o. applied.
- test substance is suspended in a carrier liquid (85 mg myrj in 100 ml 0.9% w / v NaCl solution) and the daily dose is administered in a volume of 0J mg / 100 g body weight.
- a carrier liquid 85 mg myrj in 100 ml 0.9% w / v NaCl solution
- the daily dose is administered in a volume of 0J mg / 100 g body weight.
- Therapy is started with a tumor size of 10 - 25 mm ⁇ (approx. 8 to 10 weeks after implantation) and carried out 6 times a week for 6 to 8 weeks.
- Tumor fragments with an edge length of 2 mm are implanted inguinal sc on both sides of intact rats. Depending on the growth of the tumor, new strain maintenance is started every 4-6 months.
- At least 3 different tumors are removed from the pedigree, cut into pieces with an edge length of 2 mm and implanted as described above.
- the rats are randomized to groups of 7-10 animals. One group is castrated to control androgen dependence at the start of therapy. Tumor growth is determined by determining the area of the tumor using a caliper. The tumor area is calculated from the product of the longest and the perpendicular diameter of the tumor.
- the animals are killed, the tumors. Prostate, seminal vesicles and testicles prepared and weighed.
- Average values + SE of tumor areas, tumor weights and possibly organ weights are determined. The growth course of the tumors is shown graphically.
- the statistical evaluation is carried out using the Dunnett test.
- the observed tumor growth inhibition or remission of the tumors when treated with the agent according to the invention is superior to that of the sum of the respective monotherapy with AA and PA.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU69984/94A AU6998494A (en) | 1993-05-28 | 1994-05-30 | Agents containing a compound with an anti-androgen effect and a compound with a competitive, progesterone-antagonistic effect |
EP94918820A EP0701445A1 (de) | 1993-05-28 | 1994-05-30 | Mittel, enthaltend eine verbindung mit antiandrogener sowie eine verbindung mit kompetitiver, progesteronantagonistischer wirkung |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DEP4318371.9 | 1993-05-28 | ||
DE19934318371 DE4318371A1 (de) | 1993-05-28 | 1993-05-28 | Mittel, enthaltend eine Verbindung mit antiandrogener sowie eine Verbindung mit kompetitiver, progesteronantagonistischer Wirkung |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1994027610A1 true WO1994027610A1 (de) | 1994-12-08 |
Family
ID=6489489
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1994/001756 WO1994027610A1 (de) | 1993-05-28 | 1994-05-30 | Mittel, enthaltend eine verbindung mit antiandrogener sowie eine verbindung mit kompetitiver, progesteronantagonistischer wirkung |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0701445A1 (de) |
AU (1) | AU6998494A (de) |
CA (1) | CA2163878A1 (de) |
DE (1) | DE4318371A1 (de) |
WO (1) | WO1994027610A1 (de) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999065228A2 (de) * | 1998-06-09 | 1999-12-16 | Jenapharm Gmbh & Co. Kg | Pharmazeutische kombinationen zum ausgleich eines testosteron-defizits mit schutz der prostata |
WO2002094379A1 (en) * | 2001-05-25 | 2002-11-28 | Schering Aktiengesellschaft | Use and compositions of antiprogestins for treatment of prostate diseases |
WO2003043630A1 (en) * | 2001-11-16 | 2003-05-30 | Astrazeneca Uk Limited | Solid pharmaceutical composition comprising 4-cyano-trifluoro-3-(4-fluorophenyl sulphonyl)-2-hydroxy-2-methylpropiono- m toluidide, pvp, an anti-oestrogen and/or an aromatase inhibitor |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09508125A (ja) * | 1994-01-21 | 1997-08-19 | セプラコー,インコーポレイテッド | 光学的純正r−(−)−カソデックスを使用した男性ホルモン依存疾患治療のための方法と組成 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991000733A1 (en) * | 1989-07-07 | 1991-01-24 | Endorecherche Inc. | Method of treatment of androgen-related diseases |
WO1992010194A1 (de) * | 1990-12-07 | 1992-06-25 | Schering Aktiengesellschaft Berlin Und Bergkamen | Verwendung von antigestagenen zur herstellung von arzneimitteln |
-
1993
- 1993-05-28 DE DE19934318371 patent/DE4318371A1/de not_active Withdrawn
-
1994
- 1994-05-30 EP EP94918820A patent/EP0701445A1/de not_active Withdrawn
- 1994-05-30 WO PCT/EP1994/001756 patent/WO1994027610A1/de not_active Application Discontinuation
- 1994-05-30 AU AU69984/94A patent/AU6998494A/en not_active Abandoned
- 1994-05-30 CA CA 2163878 patent/CA2163878A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991000733A1 (en) * | 1989-07-07 | 1991-01-24 | Endorecherche Inc. | Method of treatment of androgen-related diseases |
WO1992010194A1 (de) * | 1990-12-07 | 1992-06-25 | Schering Aktiengesellschaft Berlin Und Bergkamen | Verwendung von antigestagenen zur herstellung von arzneimitteln |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999065228A2 (de) * | 1998-06-09 | 1999-12-16 | Jenapharm Gmbh & Co. Kg | Pharmazeutische kombinationen zum ausgleich eines testosteron-defizits mit schutz der prostata |
WO1999065228A3 (de) * | 1998-06-09 | 2000-09-14 | Jenapharm Gmbh | Pharmazeutische kombinationen zum ausgleich eines testosteron-defizits mit schutz der prostata |
WO2002094379A1 (en) * | 2001-05-25 | 2002-11-28 | Schering Aktiengesellschaft | Use and compositions of antiprogestins for treatment of prostate diseases |
WO2003043630A1 (en) * | 2001-11-16 | 2003-05-30 | Astrazeneca Uk Limited | Solid pharmaceutical composition comprising 4-cyano-trifluoro-3-(4-fluorophenyl sulphonyl)-2-hydroxy-2-methylpropiono- m toluidide, pvp, an anti-oestrogen and/or an aromatase inhibitor |
Also Published As
Publication number | Publication date |
---|---|
CA2163878A1 (en) | 1994-12-08 |
AU6998494A (en) | 1994-12-20 |
DE4318371A1 (de) | 1994-12-01 |
EP0701445A1 (de) | 1996-03-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE3121152C2 (de) | ||
DE69532894T2 (de) | Verfahren zur empfängnisverhütung | |
DE69034148T2 (de) | Kombinationstherapie zur Prophylaxe und/oder Behandlung von gutartiger prostatischer Hyperplasie | |
EP0310541B1 (de) | Antigestagen- und antiöstrogenwirksame Verbindungen zur Geburtseinleitung und zum Schwangerschaftsabbruch sowie zur Behandlung gynäkologischer Störungen | |
DE69034035T2 (de) | Methode zur behandlung androgenbedingter krankheiten | |
DE60216630T2 (de) | Verwendung von östrogen in kombination mit progestogen für die hormonsubstitutiionstherapie | |
US4310523A (en) | Combined antiestrogens and antigonadotropically effective antiandrogens for the prophylaxis and therapy of hyperplasia of the prostate | |
DE19739916C2 (de) | Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen | |
DE60318092T2 (de) | Pharmazeutische zusammensetzung enthaltend estetrolderivate und anwendung in der krebsbehandlung | |
IL90410A (en) | A medicinal product containing estrogen and pure antiestrogen and medicinal preparations containing the product | |
EP0723439A1 (de) | Kombination von progesteronantagonisten und antiöstrogenen mit partialer agonistischer wirkung für die hormonsubstitutions-therapie für peri- und postmenopausale frauen | |
WO2013064620A1 (de) | 18-METHYL-6,7-METHYLEN-3-OXO-17-PREGN-4-EN-21,17β-CARBOLACTONE, PHARMAZEUTISCHE PRÄPARATE ENTHALTEND DIE GENANNTEN VERBINDUNGEN UND DEREN ANWENDUNG BEI DER THERAPIE DER ENDOMETRIOSE | |
WO1996019997A1 (de) | Progesteronantagonistisch- und antiöstrogen wirksame verbindungen zur gemeinsamen verwendung für die weibliche kontrazeption | |
CH648485A5 (de) | Mittel zur prophylaxe und therapie der prostatahyperplasie. | |
DE60318447T2 (de) | Pharmazeutische zusammensetzung enthaltend estetrolderivate und anwendung in der krebsbehandlung | |
EP0310542B1 (de) | Antigestagen- und antiöstrogenwirksame Verbindungen zur Behandlung hormonabhängiger Tumoren | |
WO1997032588A2 (de) | Kombination von dehydroepiandrosteron und aromatasehemmern und verwendung dieser kombination zur herstellung eines arzneimittels zur behandlung eines relativen und absoluten androgenmangels beim mann | |
DE602004009288T2 (de) | Verwendung einer kombination eines aromatasehemmers, eines progestins und eines oestrogens zur behandlung von endometriose | |
EP0701445A1 (de) | Mittel, enthaltend eine verbindung mit antiandrogener sowie eine verbindung mit kompetitiver, progesteronantagonistischer wirkung | |
WO1987005216A1 (en) | COMBINATION OF AROMATASE INHIBITORS AND 5alpha-REDUCTASE INHIBITORS | |
DE3339295C2 (de) | ||
WO2002074315A1 (de) | Pharmazeutische kombinationspräparate enthaltend aromatasehemmer und substanzen mit estrogener wirkung sowie ihre verwendung zur herstellung eines medikaments zur estrogen-ersatz-therapie | |
WO1995005828A1 (de) | PROGESTERONANTAGONISTISCH- UND ANTIÖSTROGEN WIRKSAME VERBINDUNGEN FÜR DIE BEHANDLUNG DES $i(LEIOMYOMATA UTERI) | |
DE19510862A1 (de) | Verwendung von Antiestrogenen zur männlichen Fertilitätskontrolle | |
DE4216004A1 (de) | Verwendung kompetitiver Progesteronantagonisten |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA CN CZ FI HU JP KR NO NZ PL RU SK UA US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2163878 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1994918820 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1994918820 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 1996 553343 Country of ref document: US Date of ref document: 19960405 Kind code of ref document: A |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1994918820 Country of ref document: EP |